Lupin is currently trading at Rs. 878.55, up by 8.95 points or 1.03% from its previous closing of Rs. 869.60 on the BSE.
The scrip opened at Rs. 876.25 and has touched a high and low of Rs. 885.05 and Rs. 863.50 respectively. So far 160394 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1194.00 on 15-Jun-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 885.05 and Rs. 764.00 respectively. The current market cap of the company is Rs. 39741.61 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.
Pharmaceuticals Corporation’s Tobi 300 mg/5 ml
Lupin has launched its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.
Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of around $99 million in the US (IQVIA MAT April 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
